Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas

REFERENCES

• Itkonen 0, Stenman UH, Osman S, Koivunen E, Halila H, Schröder T. Serum from pancreatecto-mised patients contain trypsinogen immunoreac-tivity. J Lab Clin Med 1996; 128: 98–102.
   Google Scholar
• Koivunen E, Huhtala ML, Stenman UH. Human ovarian tumour-associated trypsin: its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 1989; 264: 14095–9.
   Google Scholar
• Miyata S, Koshikawa N, Higashi S, Miyagi Y, Nagashima Y, Yanoma S, Kato Y, Yasumitsu H, Miyazaki K. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture. J Biochem (Tokyo) 1999; 125: 1067–76.
   Google Scholar
• Koshikawa N, Yasumitsu H, Umeda M, Miyazaki K. Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res 1992; 52: 5046–53.
   PubMed Web of Science ®Google Scholar
• Koivunen E, Saksela 0, Itkonen 0, Osman S, Huhtala ML, Stenman UH. Human colon carci-noma, fibrosarcoma and leukemia cell lines produce tumour-associated trypsinogen. Int J Cancer 1991; 47: 592–6.
   Google Scholar
• Miszczuk-Jamska B, Merten M, Guy-Crotte 0, Amouric M, Clemente F, Schoumacher R, Figarella C. Characterization of trypsinogens-1 and -2 in two human pancreatic adenocarcinoma cell lines; CFPAC-1 and CAPAN-1. FEBS Lett 1991; 294: 175–8.
   Google Scholar
• Koshikawa N, Hasegawa S, Nagashima Y. Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol 1998; 153: 937–44.
   Google Scholar
• Terada T, Kida T, Nakanuma Y. Extrahepatic peribiliary glands express alpha-amylase isozymes, trypsin and pancreatic lipase: an immunohisto-chemical analysis. Hepatology 1993; 14: 803–8.
   Google Scholar
• Paju A, Bjartell A, Zhang WM, Nordling S, Borgström A, Hansson J, Stenman UH Expres-sion and characterization of trypsinogen produced in the human male genital tract. Am J Pathol. In press.
   Google Scholar
• Kawano N, Osawa H, Ito T, Nagashima Y, Hirahara F, Inayama Y, Nakatani Y, Kimura S, Kitajima H, Koshikawa N, Miyazaki K, Kitamura H. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 1997; 28: 613–22.
   PubMed Web of Science ®Google Scholar
• Hirahara F, Miyagi E, Nagashima Y, Miyagi Y, Yasumitsu H, Koshikawa N, Nakatani Y, Nakazawa T, Udagawa K, Kitamura H, Minaguchi H, Miyazaki K. Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumours. Gynecol Oncol 1998; 68: 162–5.
   PubMed Web of Science ®Google Scholar
• Ohta T, Terada T, Nagakawa T, Tajima H, Itoh H, Fonseca L, Miyazaki I. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer 1994; 69: 152–6.
   Google Scholar
• Terada T, Ohta T, Minato H, Nakanuma Y. Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum Pathol 1995; 26: 746— 52.
   PubMed Web of Science ®Google Scholar
• Hedström J, Haglund C, Haapiainen R, Stenman UH. Serum trypsinogen-2 and trypsin-2-alphal-antitrypsin complex in malignant and benign digestive tract diseases. Preferential elevation in patients with cholangiocarcinomas. Int J Cancer 1996; 66: 326–31.
   Google Scholar
• Hedström J, Haglund C, Kemppainen E, Leinimaa M, Leinonen J, Stenman UH. Time resolved immunofluorometric assay of trypsin-1 complexed with al-antitrypsin in serum. Increased immunoreactivity in patients with biliary tract cancer. Clin Chem 1999; 45: 1768–7.
   Google Scholar
• Greene LJ, Pubols MH, Bartelt DC. Human pancreatic secretory trypsin inhibitor. Methods Enzymol 1976; 45: 813–25.
   PubMedGoogle Scholar
• Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH. Purification and characterization of a tumour-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982; 257: 13713–6.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Koivunen E, Itkonen 0. Biology and function of tumour-associated trypsin inhi-bitor, TATI. Scand J Clin Lab Invest 1991; 207 Suppl: 5–9.
   Google Scholar
• Haglund C, Huhtala ML, Halila H, Nordling S, Roberts P, Scheinin T, Stenman UH. Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer 1986; 54: 297–303.
   Google Scholar
• Ogawa M, Shibata T, Niinobu T, Uda K, Takata N, Mori T. Serum pancreatic secretory trypsin inhibitor (PSTI) in patients with inflammatory diseases. Adv Exp Med Biol 1988; 240: 505–8.
   PubMedGoogle Scholar
• Matsuda K, Ogawa M, Shibata T, Nishibe S, Miyauchi K, Matsuda Y, Mori T. Postoperative elevation of serum pancreatic secretory trypsin inhibitor. Am J Gastroenterol 1985; 80: 694–8.
   Google Scholar
• Bohe M, Lindstrom C, Ohlsson K. Varying occurrence of gastroduodenal immunoreactive pancreatic secretory trypsin inhibitor. J Clin Pathol 1987; 40: 1345–8.
   Google Scholar
• Ohmachi Y, Murata A, Matsuura N, Yasuda T, Monden M, Mori T, Ogawa M, Matsubara K. Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma. Int J Cancer 1993; 55: 728–34.
   PubMed Web of Science ®Google Scholar
• Halila H, Huhtala ML, Schroder T, Kiviluoto T, Stenman UH. Pancreatic secretory trypsin inhibitor-like immunoreactivity in pancreatecto-mised patients. Clin Chim Acta 1985; 153: 209— 16.
   Google Scholar
• Lake-Bakaar G, Dooley J. Biliary immunoreactive trypsin in man. Hepatogastroenterology 1987; 34: 103–5.
   PubMedGoogle Scholar
• Itkonen 0, Koivunen E, Hurme M, Alfthan H, Schröder T, Stenman UH. Time-resolved immuno-fluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 1990; 115: 712–8.
   Google Scholar
• Osman S, Turpeinen U, Itkonen 0, Stenman UH. Optimization of a time-resolved immunofluoro-metric assay for tumour-associated trypsin inhi-bitor (TATI) using the streptavidin-biotin system. J Immunol Methods 1993; 161: 97–106.
   Google Scholar
• von Boguslawsky K. Immunohistochemical detec-tion of progesterone receptors in paraffin sections. A novel method using microwave oven pretreat-ment. Apmis 1994; 102: 641–6.
   Google Scholar
• Lukkonen A, Lintula S, Boguslawski K, Carpen 0, Ljungberg B, Landberg G, Stenman UH. Tumour-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer 1999; 83: 486–90.
   Google Scholar
• Kobayashi K, Nakata M, Terazono H, Shinsato T, Saheki T. Pancreatic secretory trypsin inhibitor gene is highly expressed in the liver of adult-onset type II citrullinemia. FEBS Lett 1995; 372: 69–73.
   Google Scholar
• Koivunen E, Ristimäki A, Itkonen 0, Osman S, Vuento M, Stenman UH. Tumour-associated trypsin participates in cancer cell-mediated degra-dation of extracellular matrix. Cancer Research 1991; 51: 2107–12.
   Google Scholar
• Huhtala ML, Kahanpää K, Seppälä M, Halila H, Stenman UH. Excretion of a tumour-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer 1983; 31: 711–4.
   PubMed Web of Science ®Google Scholar
• Yasuda T, Ogawa M, Murata A, Ohmachi Y, Mori T, Matsubara K. Identification of the IL-6-responsive element in an acute-phase- responsive human pancreatic secretory trypsin inhibitor-encoding gene. Gene 1993; 131: 275–80.
   PubMed Web of Science ®Google Scholar